ADD/ADHD Rx for Mental Disorder: 67.3% of denials overturned
In 55 California IMR decisions from 2019 to 2025, reviewers overturned 37 (67.3%). In the last five years: 63.6% of 44. 54 were medical-necessity disputes, 1 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 8 | 62.5% |
| 2022 | 7 | 100.0% |
| 2023 | 10 | 80.0% |
| 2024 | 9 | 55.6% |
| 2025 | 10 | 30.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 25 | 68.0% | 67.3% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 9 | 55.6% | 67.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 6 | 0.0% | 67.3% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 6 | 66.7% | 67.3% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 5 | 40.0% | 67.3% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 5 | 40.0% | 67.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for the brand name medication, Concerta. Stimulant medications, including methylphenidate formulations, are first-line pharmacological treatment for patients with attention-deficit hyperactivity disorder (ADHD). Approximately 70% of patients with ADHD demonstrate immediate improvement in attentiveness and reduced distractibility with stimulant therapy, with moderate-to-large effect sizes. Extended-release (ER) …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Quillivant XR 25 mg/5 mL.The records document that this patient has a history of attention-deficit/hyperactivity disorder (ADHD). The patient and provider report that the patient was previously stable on Quillivant XR 25 mg/5 mL for longer than one year. The provider noted …”
“The physician reviewer found that an enrollee has requested authorization and coverage for lisdexamfetamine dimesylate capsules. Lisdexamfetamine is an FDA‑approved long‑acting stimulant for adult attention‑deficit/hyperactivity disorder and has strong evidence supporting its effectiveness compared to placebo and other stimulant medications. In adults who have previously used short‑acting amphetamines, lisdexamfetamine provides benefits such as once‑daily dosing, improved adherence, and a lower …”
And one the reviewer upheld
“The physician reviewer found that a patient has requested authorization and coverage for brand name Adderall. Clinical guidelines recommend amphetamine-based stimulants as first-line therapy for patients with attention-deficit hyperactivity disorder (ADHD). The medical literature does not demonstrate efficacy or safety of brand-name formulations over generic formulations. This patient has reported negative side effects to one generic stimulant formulation. In this …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were ADD/ADHD Rx denials for Mental Disorder overturned?
In 55 California IMR decisions from 2019 to 2025, reviewers overturned 37 (67.3%). In the last five years: 63.6% of 44. 54 were medical-necessity disputes, 1 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.